ADC Therapeutics Reports Q1 2026 Financial Results with $20.9M Revenue and $33M Net Loss

ADC Therapeutics SA reported its financial results for the first quarter of 2026, revealing a total revenue of $20.9 million, a decrease of 9.5% compared to $23.0 million in the same period last year. The decline was primarily driven by a significant drop in license revenues and royalties, which fell to $0.8 million from $5.6 million, largely due to a one-time milestone payment recognized in the prior year. In contrast, product revenues from ZYNLONTA increased by 15.1% to $20.0 million, reflecting higher sales volume and pricing.

The company's operating expenses for the quarter were $46.1 million, down 10.5% from $51.5 million in the previous year. This reduction was attributed to a 31.3% decrease in research and development expenses, which totaled $19.9 million, as the company shifted focus following its 2025 restructuring plan. The restructuring involved discontinuing certain preclinical programs and reducing the workforce by approximately 30%. Despite the overall decrease in expenses, costs associated with product sales rose significantly by 75.4% to $3.6 million, driven by increased personnel costs and higher shipping and storage charges.

ADC Therapeutics reported a net loss of $33.0 million for the quarter, an improvement from a net loss of $38.6 million in the same period last year. The loss per share was $0.21, compared to $0.36 in the prior year. The company noted that the decrease in net loss was influenced by lower operating costs and a favorable change in the fair value of its HCR warrant obligation, which contributed $2.2 million to other income.

In terms of operational metrics, ADC Therapeutics maintained a cash position of $231.0 million as of March 31, 2026, down from $261.3 million at the end of 2025. The company continues to focus on expanding ZYNLONTA's market presence, including ongoing clinical trials aimed at exploring its use in earlier lines of therapy and in combination with other treatments. The company is also pursuing strategic collaborations and financing opportunities to support its growth initiatives.

Looking ahead, ADC Therapeutics anticipates continued investment in its research and development efforts, particularly for ZYNLONTA, while managing its operating expenses in line with its restructuring strategy. The company remains committed to leveraging its existing cash resources and potential revenue streams to fund its operations and capitalize on market opportunities in the antibody drug conjugate space.